Market Place
Sourcing Support
Lilly Drafts Plan For Last Of 4 New US Drug Manufacturing Plants
01 Feb 2026 //
FIERCE PHARMA
Ascletis to Develop ASC37 Triple Agonist
20 Jan 2026 //
PR NEWSWIRE
Protheragen Tackles FDA Drug Shortages with GLP-1 API Expansion
19 Dec 2025 //
PHARMIWEB
Lilly`s obesity triple threat tops phase 3 efficacy forecasts
11 Dec 2025 //
PR NEWSWIRE
Ascletis Selects ASC37: First Oral Triple Agonist
30 Nov 2025 //
PR NEWSWIRE
Umbrella Labs Launches Retatrutide for Scientific Research
20 Jun 2025 //
ACCESSWIRE
Umbrella Labs Adds Retatrutide (LY3437943) to Research Portfolio
02 Jun 2025 //
ACCESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.